DOI QR코드

DOI QR Code

Carotenoids가 인체의 대장암 세포인 HT-29 세포의 증식에 미치는 영향

Effect of Carotenoids on the Growth of HT-29 Human Colon Cancer Cells

  • 김은지 (한림대학교 실버생물산업기술연구센터) ;
  • 정재인 (한림대학교 생명과학부) ;
  • 이현숙 (한림대학교 생명과학부) ;
  • 강일준 (한림대학교 생명과학부) ;
  • ;
  • 윤정한 (한림대학교 생명과학부)
  • ;
  • ;
  • ;
  • ;
  • Frederick Khachik (Joint Institute for Food Safety & Applied Nutrition, University of Maryland) ;
  • 발행 : 2003.04.01

초록

Carotenoids는 항암 효과가 있는 것으로 알려져 있으나 각각의 carotenoids가 대장암에 미치는 영향에 대해서는 명확하게 밝혀진 바가 없다. 본 연구에서는 4가지 종류의 carotenoids가 인간의 대장에서 유래한 암세포인 HT-29 세포의 증식에 미치는 영향을 조사하였다. $\alpha$-carotene, $\beta$-carotene, lutein lycopene을 농도를 달리 하여 세포 배양액 에 첨가하여 살아있는 세포의 수를 측정한 결과 $\beta$-carotene는 세포의 증식을 다소 증가시키는 반면 $\alpha$-carotene, lutein, lcopene은 세포의 증식을 감소하였다. 세포의 증식을 억제한 carotenoids 중에서 lycopene이 그 효과가 가장 컸다. ErbB receptor family는 세포의 증식을 촉진하고 대장암에서 그 발현이 증가된 것으로 보고되었기 때문에 lycopene이 heregulin-ErbB3 signaling을 억제하는지를 조사하였다. Lycopene는 ErbB2 단백질을 감소하였고 ErbB3 단백질의 변화를 초래하였다. Heregulin을 첨가하여 인산화를 유도한 경우 ErbB3의 인산화, ErbB3와 p85의 결합, Akt 인산화가 lycopene에 의해 억제되었다. 이 결과들은 carotenoids 중 lycopene이 대장암 세포 증식 억제 효과가 가장 크고, 대장암 세포의 DNA 합성을 억제하고 apoptosis를 유도하는 lycopene효과의 일부는 Erb-B3와 Akt의 인산화 감소에 기인하는 것임을 나타낸다.

참고문헌

  1. Doll R, Peto R. 1981. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66: 1191-1308.
  2. Weisburger JH. 1991. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 53 (Suppl.): 226S-237S. https://doi.org/10.1093/ajcn/53.1.226S
  3. Ziegler RG. 1991. Vegetables, fruits, and carotenoids and the risk of cancer. Am J Clin Nutr 53 (Suppl.): 251S-259S. https://doi.org/10.1093/ajcn/53.1.251S
  4. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. 1996. Lack of effect of long-term supplementation with $\beta$-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334: 1145-1149. https://doi.org/10.1056/NEJM199605023341801
  5. Greenberg ER, Baron JA, Tosteson TD, Freeman DH, Beck GJ, Bond JH, Colacchio TA, Coller JA, Frankl HD, Haile RW, Mandel JS, Nierenberg DW, Rothstein R, Snover DC, Stevens MM, Summers RW, van Stolk RU, The Polps Prevention Study Group. 1994. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 331: 141-147. https://doi.org/10.1056/NEJM199605023341801
  6. Beta Carotene Cancer Prevention Study Group The Alphatocopherol. 1994. Effect of vitamin E and $\beta$-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029-1035. https://doi.org/10.1056/NEJM199404143301501
  7. Zhang SM, Tang GW, Russell RM, Mayzel KA, Stempfer MJ, Willet WC, Hunter DJ. 1997. Measurement of retinoids and carotenoids in breast adipose tissue and a comparision of concentrations in breast cancer cases and control subjects. Am J Clin Nutr 334: 626-632
  8. Goodman MT, Kolonel LN, Wilkens LR, Yoshizawa CN, Lemarchand L, Hankin JH. 1992. Dietary factors in lung cancer prognosis. Eur J Cancer 28: 495-501. https://doi.org/10.1016/S0959-8049(05)80086-3
  9. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. 1995. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87: 1767-1776. https://doi.org/10.1093/jnci/87.23.1767
  10. Giovannucci E. 1999. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 91: 317-331 https://doi.org/10.1093/jnci/91.4.317
  11. Kim DJ, Takasuka N, Kim JM, Sekine K, Ota T, Asamoto M, Murakoshi M, Nishino H, Nir Z, Tsuda H. 1997. Chemoprevention by lycopene of mouse lung neoplasia after combined initiation treatment with DEN, MNU and DMH. Cancer Lett 120: 15-22. https://doi.org/10.1016/S0304-3835(97)00281-4
  12. Wang C-J, Lin J-K. 1989. Inhibitory effects of carotenoids and retinoids on the in vitro growth of rat C-6 glioma cells. Proc Natl Sci Counc Repub China B 13: 176-183.
  13. Amir H, Karas M, Giat J, Danilenko M, Levy R, Yermiahu T, Levy J, Sharoni Y. 1999. Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr Cancer 33: 105-112. https://doi.org/10.1080/01635589909514756
  14. Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411: 355-365.
  15. Toyoda H, Komurasaki T, Ikeda Y, Yoshimoto M, Morimoto S. 1995. Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development. FEBS Lett 377: 403-407. https://doi.org/10.1016/0014-5793(95)01403-9
  16. Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu N, Yayon A, Wen D. 1994. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J Biol Chem 269: 25226-25233.
  17. Varticovski L, Harrison-Findik D, Keeler ML, Susa M. 1994. Role of PI3-kinase in mitogenesis. Biochim Biophys Acta 1226: 1-11. https://doi.org/10.1016/0925-4439(94)90051-5
  18. Toker A, Cantley LC. 1997. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387: 673-676. https://doi.org/10.1038/42648
  19. Klippel A, Kavanaugh WM, Pot D, Williams LT. 1997. A specific product of phophatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol 17: 338-344. https://doi.org/10.1128/MCB.17.1.338
  20. Datta SR, Brunet A, Greenberg M. 1999 Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927. https://doi.org/10.1101/gad.13.22.2905
  21. Salomon DS, Brandt R, Ciardiello F, Normanno N. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232. https://doi.org/10.1016/1040-8428(94)00144-I
  22. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Sciences 244: 707-712. https://doi.org/10.1126/science.2470152
  23. Safran H, Steinhoff M, Mangray S, Rathore R, King TC, Chai L, Berzein K, Moore T, Iannitti D, Reiss P, Pasquariello T, Akerman P, Quirk D, Mass R, Goldstein L, Tantravahi U. 2001. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 24: 496-499. https://doi.org/10.1097/00000421-200110000-00016
  24. Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, Korc M, Buchler MW. 1998. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 29: 771-777. https://doi.org/10.1016/S0046-8177(98)90444-0
  25. Denizot F, Lanf H. 1986. Rapid colorimetric assay for cell growth and survival modifications to the tetrazolium dye procedure giving improved sensivity and reliability. J Immunological Methods 89: 271-277. https://doi.org/10.1016/0022-1759(86)90368-6
  26. Ziegler RG, Colavito EA, Hartge P, McAdams MJ, Schoenberg JB, Mason TJ, Fraumeni JF Jr. 1996. Importance of alphacarotene, beta-carotene, and other phytochemicals in the etiology of lung cancer. J Natl Cancer Inst 88: 612-615. https://doi.org/10.1093/jnci/88.9.612
  27. Kotake-Nara E, Kushiro M, Zhang H, Sugawara T, Miyashita K, Nagao A. 2001.Carotenoids affect proliferation of human prostate cancer cells. J Nutr 131: 3303-3306.
  28. Levy J, Bosin E, Feldman B, Giat Y, Miinster A, Danilenko M, Sharoni Y. 1995. Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. Nutr Cancer 24: 257-266. https://doi.org/10.1080/01635589509514415
  29. Narisawa T, Fukaura Y, Hasebe M, Ito M, Aizawa R, Murakoshi M, Uemura S, Khachik F, Nishino H. 1996. Inhibitory effects of natural carotenoids, alpha-carotene, betacarotene, lycopene and lutein, on colonic aberrant crypt foci formation in rats. Cancer Lett 107: 137-142. https://doi.org/10.1016/0304-3835(96)04354-6
  30. Zhang LX, Cooney RV, Bertram JS. 1991. Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: relationship to their cancer chemopreventive action. Carcinogenesis 12: 2109-2114. https://doi.org/10.1093/carcin/12.11.2109
  31. Palozza P, Serini S, Maggiano N, Angelini M, Boninsegna A, Di Nicuolo F, Ranelletti FO, Calviello G. 2002. Induction of cell cycle arrest and apoptosis in human colon adenocarcinoma cell lines by beta-carotene through down-regulation of cyclin A and Bcl-2 family proteins. Carcinogenesis 23: 11-18. https://doi.org/10.1093/carcin/23.1.11
  32. Anderson NG, Ahmad T. 2002. ErbB receptor tyrosine ki-nase inhibitiors as therapeutic agents. Front Biosci 7: 1926-1940. https://doi.org/10.2741/anderson
  33. Motoyama AB, Hynes NE, Lane HA. 2002. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62: 3151-3158.
  34. Ram TG, Hosick HL, Ethier SP. 2000. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells. J Cell Physiol 183: 301-313. https://doi.org/10.1002/(SICI)1097-4652(200006)183:3<301::AID-JCP2>3.0.CO;2-W
  35. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL 3rd. 1994. Insect cell-expressed p180 erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 91: 8132-8136. https://doi.org/10.1073/pnas.91.17.8132
  36. Alroy I, YardenY. 1997. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410: 83-86. https://doi.org/10.1016/S0014-5793(97)00412-2
  37. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL 3rd. 1994. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269: 14661-14665.
  38. Hellyer NJ, Kim HH, Greaves CH, Sierke SL, Koland JG. 1995. Cloning of the rat ErbB3 cDNA and characterization of the recombinant protein. Gene 165: 279-284. https://doi.org/10.1016/0378-1119(95)00436-A
  39. Kim D, Chung J. 2002. Akt: Versatile mediator of cell survival and beyond. J Biochem Mol Biol 35: 106-115. https://doi.org/10.5483/BMBRep.2002.35.1.106
  40. Kandel ES, Hay N. 1999. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253: 210-229. https://doi.org/10.1006/excr.1999.4690
  41. Nicholson KM, Anderson NG. 2002. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381-395. https://doi.org/10.1016/S0898-6568(01)00271-6